BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33482697)

  • 1. A vasculature-centric approach to developing novel treatment options for glioblastoma.
    Wirsching HG; Roth P; Weller M
    Expert Opin Ther Targets; 2021 Feb; 25(2):87-100. PubMed ID: 33482697
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
    Takano S
    Brain Tumor Pathol; 2012 Apr; 29(2):73-86. PubMed ID: 22218709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.
    Ishikawa E; Miyazaki T; Takano S; Akutsu H
    Brain Tumor Pathol; 2021 Jul; 38(3):149-155. PubMed ID: 33977360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
    Ahir BK; Engelhard HH; Lakka SS
    Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
    Ramjiawan RR; Griffioen AW; Duda DG
    Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
    de Boüard S; Guillamo JS
    Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
    Wang N; Jain RK; Batchelor TT
    Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
    Pellerino A; Bruno F; Soffietti R; Rudà R
    Curr Oncol Rep; 2023 Jul; 25(7):777-785. PubMed ID: 37071295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab antiangiogenic therapy for glioblastoma.
    Junck L
    Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
    [No Abstract]   [Full Text] [Related]  

  • 13. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
    Anthony C; Mladkova-Suchy N; Adamson DC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in glioblastoma multiforme: navigating the maze.
    Linkous AG; Yazlovitskaya EM
    Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for glioblastoma.
    Gerstner ER; Batchelor TT
    Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
    de Groot J; Reardon DA; Batchelor TT
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of VEGF in the treatment of glioblastoma.
    Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS
    Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.
    He B; Jabouille A; Steri V; Johansson-Percival A; Michael IP; Kotamraju VR; Junckerstorff R; Nowak AK; Hamzah J; Lee G; Bergers G; Ganss R
    J Pathol; 2018 Jun; 245(2):209-221. PubMed ID: 29603739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.